Extranodal NK-T-cell lymphoma primary prevention: Difference between revisions
Created page with "__NOTOC__ {{Extranodal NK-T-cell lymphom}} {{CMG}}; {{AE}} ==Overview== There are no established measures for the primary prevention of [disease name]. OR There are no ava..." |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Extranodal NK-T-cell | {{Extranodal NK-T-cell lymphoma}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} | ||
Revision as of 20:45, 23 August 2019
Extranodal NK-T-cell lymphoma Microchapters |
Differentiating Extranodal NK-T-cell lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Extranodal NK-T-cell lymphoma primary prevention On the Web |
American Roentgen Ray Society Images of Extranodal NK-T-cell lymphoma primary prevention |
Extranodal NK-T-cell lymphoma primary prevention in the news |
Risk calculators and risk factors for Extranodal NK-T-cell lymphoma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the primary prevention of [disease name].
OR
There are no available vaccines against [disease name].
OR
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
Primary Prevention
There are no established measures for the primary prevention of [disease name].
OR
There are no available vaccines against [disease name].
OR
Effective measures for the primary prevention of [disease name] include:
- [Measure1]
- [Measure2]
- [Measure3]
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]